Acyl-CoA synthetases (ACSL) activate long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. ACSL5 may activate fatty acids from exogenous sources for the synthesis of triacylglycerol destined for intracellular storage. Utilizes a wide range of saturated fatty acids with a preference for C16-C18 unsaturated fatty acids. It was suggested that it may also stimulate fatty acid oxidation. At the villus tip of the crypt-villus axis of the small intestine may sensitize epithelial cells to apoptosis specifically triggered by the death ligand TRAIL. May have a role in the survival of glioma cells.
ACSL5 Polyclonal Antibody. Unconjugated. Raised in: Rabbit.
Liquid. 0.03% Proclin 300, 50% Glycerol, 0.01M PBS, PH 7.4.
>95%, Protein G purified
Recombinant Human Long-chain-fatty-acid--CoA ligase 5 protein (33-683AA)
Shipped at 4°C. Upon delivery aliquot and store at -20°C (short-term) or -80°C (long-term). Avoid repeated freeze.
Long-chain-fatty-acid--CoA ligase 5, Long-chain acyl-CoA synthetase 5, LACS 5, ACSL5, ACS5, FACL5, UNQ633/PRO1250
ELISA, WB, IHC; Recommended dilution: WB:1:500-5000, IHC:1:20-1:200